DongKoo Bio&Pharma Co. Ltd (006620) — Cash Flow-to-Debt Ratio
DongKoo Bio&Pharma Co. Ltd (006620) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of ₩1.20 Billion could theoretically repay 0% of its total liabilities (₩158.34 Billion) in one year. See DongKoo Bio&Pharma Co. Ltd (006620) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
DongKoo Bio&Pharma Co. Ltd Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for DongKoo Bio&Pharma Co. Ltd across 10 annual periods. Also explore 006620 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for DongKoo Bio&Pharma Co. Ltd (2015–2024)
Year-by-year debt coverage analysis for DongKoo Bio&Pharma Co. Ltd. For market capitalisation and broader financial context, see market cap of DongKoo Bio&Pharma Co. Ltd.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.13x | ₩17.34 Billion | ₩138.73 Billion | ▲ +181.3% |
| 2023 | 0.04x | ₩3.59 Billion | ₩80.66 Billion | ▼ -81.5% |
| 2022 | 0.24x | ₩16.82 Billion | ₩69.95 Billion | ▼ -26.6% |
| 2021 | 0.33x | ₩17.90 Billion | ₩54.66 Billion | ▲ +117.4% |
| 2020 | 0.15x | ₩7.49 Billion | ₩49.70 Billion | ▼ -30.0% |
| 2019 | 0.22x | ₩10.14 Billion | ₩47.07 Billion | ▲ +976.1% |
| 2018 | -0.02x | ₩-791.20 Million | ₩32.18 Billion | ▼ -109.8% |
| 2017 | 0.25x | ₩9.51 Billion | ₩37.85 Billion | ▼ -13.7% |
| 2016 | 0.29x | ₩12.59 Billion | ₩43.27 Billion | ▲ +144.3% |
| 2015 | 0.12x | ₩6.93 Billion | ₩58.22 Billion | — |